CSIMarket
 


Achieve Life Sciences Inc   (ACHV)
Other Ticker:  
 

Achieve Life Sciences Inc 's Quick Ratio

ACHV's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 4.88 above Achieve Life Sciences Inc average.

Within In Vitro & In Vivo Diagnostic Substances industry 2 other companies have achieved higher Quick Ratio than Achieve Life Sciences Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 461 to 539.

Explain Quick Ratio?
How much Cash & cash equivalents ACHV´s has?
What are ACHV´s Current Liabilities?


ACHV Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -40.98 % -35.68 % 406.26 % 374.7 % 124.84 %
Y / Y Cash & cash equivalent Change 9.46 % -14.66 % -54.55 % -42.42 % -45.37 %
Quick Ratio MRQ 4.88 7.27 0.81 1.15 2.63
ACHV's Total Ranking # 539 # 461 # 1536 # 1337 # 1105
Seq. Current Liabilities Change 18.42 % -83.02 % -6.01 % 212.3 % 29.05 %
Seq. Cash & cash equivalent Change -20.55 % 51.82 % -33.33 % 36.13 % -38.06 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 3
Healthcare Sector # 309
Overall Market # 539


Quick Ratio Statistics
High Average Low
12.22 4.76 0.81
(Dec 31 2020)   (Mar 31 2023)




Financial Statements
Achieve Life Sciences Inc 's Current Liabilities $ 4 Millions Visit ACHV's Balance sheet
Achieve Life Sciences Inc 's Cash & cash equivalent $ 20 Millions Visit ACHV's Balance sheet
Source of ACHV's Sales Visit ACHV's Sales by Geography


Cumulative Achieve Life Sciences Inc 's Quick Ratio

ACHV's Quick Ratio for the trailling 12 Months

ACHV Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -40.98 % -35.68 % 406.26 % 374.7 % 124.84 %
Y / Y Cash & cash equivalent TTM Growth 9.46 % -14.66 % -54.55 % -42.42 % -45.37 %
Quick Ratio TTM 1.75 1.62 1.64 2.87 6.09
Total Ranking TTM # 1038 # 1179 # 1287 # 1064 # 604
Seq. Current Liabilities TTM Growth 18.42 % -83.02 % -6.01 % 212.3 % 29.05 %
Seq. Cash & cash equivalent TTM Growth -20.55 % 51.82 % -33.33 % 36.13 % -38.06 %


On the trailing twelve months basis ACHV Cash & cash equivalent improved by 9.46 % in III Quarter 2023 year on year, while Current Liabilities increased to $4 millions, this led to increase in in Achieve Life Sciences Inc 's Quick Ratio to 1.75, Quick Ratio remained below ACHV average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 16 other companies have achieved higher Quick Ratio than Achieve Life Sciences Inc . While Quick Ratio overall ranking has improved so far to 3680, from total ranking during the twelve months ending second quarter 2023 at 3836.

Explain Quick Ratio?
How much Cash & cash equivalents ACHV´s has?
What are ACHV´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the In Vitro & In Vivo Diagnostic Substances Industry # 17
Healthcare Sector # 1007
Within the Market # 539


trailing twelve months Quick Ratio Statistics
High Average Low
10.14 4.57 1.62
(Dec 31 2020)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within In Vitro & In Vivo Diagnostic Substances Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Intellia Therapeutics Inc   9.30 $ 854.788  Millions$ 91.953  Millions
Celldex Therapeutics inc   8.45 $ 235.348  Millions$ 27.836  Millions
Achieve Life Sciences Inc   4.88 $ 19.919  Millions$ 4.082  Millions
Biomerica Inc   4.58 $ 7.988  Millions$ 1.746  Millions
Alpha Teknova Inc   3.85 $ 32.079  Millions$ 8.339  Millions
Lantheus Holdings Inc   3.48 $ 614.131  Millions$ 176.602  Millions
Neogen Corporation  1.73 $ 239.256  Millions$ 138.130  Millions
Oncocyte Corporation  1.72 $ 13.783  Millions$ 8.033  Millions
Mymd Pharmaceuticals Inc   1.49 $ 8.473  Millions$ 5.696  Millions
Cardio Diagnostics Holdings Inc   1.31 $ 3.630  Millions$ 2.777  Millions
Aspira Women s Health Inc   1.04 $ 5.100  Millions$ 4.926  Millions

Date modified: 2023-11-12T11:54:30+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com